Depressive disorders -- is it time to endorse different pathophysiologies?
about
Mood disorders in Huntington's disease: from behavior to cellular and molecular mechanismsGlucocorticoid dysregulations and their clinical correlates. From receptors to therapeuticsHerbal Medicine for Anxiety, Depression and InsomniaLate-Onset Cognitive Impairments after Early-Life Stress Are Shaped by Inherited Differences in Stress Reactivity.Sleep disturbances in highly stress reactive mice: modeling endophenotypes of major depression.Association of limbic system-associated membrane protein (LSAMP) to male completed suicide.Rhythmicity in mice selected for extremes in stress reactivity: behavioural, endocrine and sleep changes resembling endophenotypes of major depressionStress and depression: preclinical research and clinical implicationsThe influence of 5-HTTLPR genotype on the association between the plasma concentration and therapeutic effect of paroxetine in patients with major depressive disorder.The development of an RDoC-based treatment program for adolescent depression: "Training for Awareness, Resilience, and Action" (TARA)Integration of animal behaviors under stresses with different time courses.Cerebrospinal fluid space alterations in melancholic depression.Protective effect of sex on chronic stress- and depressive behavior-induced vascular dysfunction in BALB/cJ mice.Latent Classes of Symptoms related to Clinically Depressed Mood in Adolescents.Integrated behavioral z-scoring increases the sensitivity and reliability of behavioral phenotyping in mice: relevance to emotionality and sexModeling treatment-resistant depression.Mind matters in cancer survival.Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 BalanceMetabolomic biosignature differentiates melancholic depressive patients from healthy controls.Gender Differences in Depressive Symptom Profile: Results from Nationwide General Population Surveys in KoreaTrajectories of internalizing symptoms across childhood: The roles of biological self-regulation and maternal psychopathology.Neurobiological processes in adolescent addictive disorders.Hippocampal volumes and depression subtypes.Serum brain-derived neurotrophic factor, vascular endothelial growth factor and leptin levels in patients with a diagnosis of severe major depressive disorder with melancholic features.Neglected children, shame-proneness, and depressive symptoms.Incorporating hypothalamic-pituitary-adrenal axis measures into preventive interventions for adolescent depression: are we there yet?Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression.Early Life Stress in Depressive Patients: HPA Axis Response to GR and MR Agonist.Cortisol awakening response and subsequent depression: prospective longitudinal study.Disruption of fetal hormonal programming (prenatal stress) implicates shared risk for sex differences in depression and cardiovascular disease.Sex differences in the prediction of the effectiveness of paroxetine for patients with major depressive disorder identified using a receiver operating characteristic curve analysis for early response.Prospective associations of depression subtypes with cardio-metabolic risk factors in the general population.Atypical depression and alcohol misuse are related to the cardiovascular risk in the general population.Inverse correlation between clinical response to paroxetine and plasma drug concentration in patients with major depressive disorders.Major depression in young girls is related to altered cortisol awakening response.Behavioural signs of depression and apoptosis in the limbic system following myocardial infarction: effects of sertraline.Thyrotropin serum concentrations in healthy volunteers are associated with depression-related personality traits.Ketamine-Induced Glutamatergic Mechanisms of Sleep and Wakefulness: Insights for Developing Novel Treatments for Disturbed Sleep and Mood.Depressive symptom composites associated with cortisol stress reactivity in adolescents.Creatine Prevents Corticosterone-Induced Reduction in Hippocampal Proliferation and Differentiation: Possible Implication for Its Antidepressant Effect.
P2860
Q21131050-6887FDD0-EFBB-4B38-BA04-AB63D237BCF0Q24618470-18B6A6DF-9721-4BC2-A5B0-23F9BACD3117Q26786225-C9580A35-8AE7-4DC7-B50F-FD1AD34BF008Q30838467-2F8694A0-76B3-467E-9FD9-A00E088D2284Q31004468-987F104A-EB7B-4E1B-9035-6995DD215058Q33330477-B42A2CA7-AAD2-4C94-8B59-9D73D752502EQ33403741-3E36DD63-6404-488E-A206-E8983ACF2BC2Q33404098-C9B6FDE1-5604-4DF6-9B23-42CFE227CF4CQ33654737-FA1CB655-72A1-4E1E-B049-39C00225E5C2Q34063322-ABE47476-96DB-4D88-BC33-AC83F1B82A8BQ34319489-513AEDA6-74BB-4966-916F-4311B7D9174DQ34325687-FAC446FA-1073-41D3-8692-6CD0B59FCD84Q34440180-EABACBDA-8C40-4EB1-B967-CA5DC191F28AQ34539573-3CE69A8B-884C-4698-8D6C-44F31DCE6493Q34906869-9872653B-B37A-47D0-B001-F77AF8DAA9B3Q35032461-0ADEE573-D828-4927-9B8E-8A3B131962CAQ36016346-D5AB407F-6F77-4191-9B0B-0EFA09327868Q36067334-C002CD12-BE88-48BA-9EBD-1F05D5C7FD60Q36109672-18D13DA3-A417-48D0-A134-17AF8A653DC9Q36241751-44A2DEB0-E3E8-4A54-9631-32AEC326A2D3Q36369922-965F9D23-00B0-4146-B5CE-AEAB7001CEE1Q36508688-9170FDEE-98F0-4BA9-9EFD-315D6046DDA8Q36793989-40074ED6-3EA6-402E-AF3A-54867A1656D1Q37079021-43143AC6-08DC-44B5-9E69-1CC217BA2399Q37167216-32E0BEC1-8ACF-46C4-82AB-95392B550784Q37208947-7550F058-DFDE-43E4-BD79-BE60223F6C34Q37380865-92F25F87-5AB2-4D67-88F6-F4D48B40B824Q37510945-2D468FA5-8986-441F-99F7-78D6232FF0F3Q37541162-91AF626B-AE63-4FE9-B8CF-6C7121339E48Q37566350-B68C75A5-9A92-47B5-9F98-CB8707675648Q37702179-8E0321CA-5620-425F-89BE-7A2834EA7FABQ39304122-4D5A6157-6C8A-48FF-A0F1-66942E16EABEQ40078755-7DCE7F3E-E9A2-412C-B5DB-B8EB501ED8CCQ43415647-5716E193-F3B2-4DCC-87A9-605ADA82F191Q46083776-695ABA2B-3828-4580-837B-AA6EB2D2A327Q46533451-3FE1F376-11AE-4D1C-B2A2-7E69874A34A8Q46817088-35DCA3C1-2065-425E-9295-13CBB3E017D6Q47615913-C36BF2E6-45B7-42A8-AAE7-05CBD4DE6908Q48001214-57D24B9D-BA79-42C9-AB5F-B03952671B0AQ48039679-BEC4B73A-8452-4365-8DF2-7FB02804CCFD
P2860
Depressive disorders -- is it time to endorse different pathophysiologies?
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Depressive disorders -- is it time to endorse different pathophysiologies?
@ast
Depressive disorders -- is it time to endorse different pathophysiologies?
@en
type
label
Depressive disorders -- is it time to endorse different pathophysiologies?
@ast
Depressive disorders -- is it time to endorse different pathophysiologies?
@en
prefLabel
Depressive disorders -- is it time to endorse different pathophysiologies?
@ast
Depressive disorders -- is it time to endorse different pathophysiologies?
@en
P1476
Depressive disorders -- is it time to endorse different pathophysiologies?
@en
P2093
Irina A Antonijevic
P356
10.1016/J.PSYNEUEN.2005.04.004
P577
2005-06-13T00:00:00Z